ECDC: around 9 million Europeans are affected by chronic hepatitis B or C
An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million (3.9) with chronic hepatitis C infection. However, large numbers of them are not even aware of their infection as they have not yet been tested and diagnosed.
EMCDDA and ECDC join forces to address the challenge of hepatitis
Hepatitis and other drug-related infectious diseases will be the focus of ‘Hepatitis week’, taking place at the EU drugs agency (EMCDDA) in Lisbon from 12–16 June 2017. The initiative will bring together some 100 specialists from: EU Member States, candidate and potential candidate countries to the EU, as well as partner agencies, civil society and professional organisations.
Adoption of regional hepatitis action plan by WHO Regional Committee
This first European Action Plan provides an important driver to aid countries in their fight against viral hepatitis, to which ECDC had the opportunity to contribute directly.
Viral hepatitis: testing saves lives
Every year, around 50 000 newly diagnosed cases of hepatitis B and C are reported across Europe but millions are unaware of their infection. Left untreated, hepatitis can cause irreversible liver damage. Hepatitis A is recognised as a re-emerging health threat in Europe.